Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00930_DB00991_nanopub.RA4q3wAwdajXc6SGbmvMUaRw11VUhY9SZSFQHt8etPmN4#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00930_DB00991 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00930_DB00991 label "DDI between Colesevelam and Oxaprozin - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. [drugbank_resource:DB00930_DB00991]" assertion.
- drugbank_resource:DB00930_DB00991 identifier "drugbank_resource:DB00930_DB00991" assertion.
- drugbank_resource:DB00930_DB00991 title "DDI between Colesevelam and Oxaprozin - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam." assertion.
- drugbank:DB00930 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00930_DB00991 assertion.
- drugbank:DB00991 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00930_DB00991 assertion.